Case Report

Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315040, China

Department of Cardiology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315040, China

Search for more papers by this author

Yi Lu

*Author for correspondence:

E-mail Address: 37263205@qq.com

https://orcid.org/0000-0002-2240-6824

Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315040, China

Search for more papers by this author

Published Online:5 Feb 2024https://doi.org/10.2217/imt-2023-0084

View article

Abstract

Radiation-induced coronary artery disease (RICAD) poses a serious concern for cancer patients post radiotherapy, typically emerging after over a decade. Immune checkpoint inhibitors (ICIs), known for cardiotoxicity, are increasingly recognized for causing cardiovascular complications. Here we report the case of a 63-year-old man with metastatic lung cancer who developed coronary artery disease during his third-line therapy with an ICI (nivolumab) and an antiangiogenic agent (bevacizumab), 3 years post chest radiotherapy. Angiography revealed relatively isolated stenosis in the left main coronary artery ostium, consistent with the radiotherapy site, with no other risk factors, suggesting RICAD. The potential for ICIs to accelerate RICAD development should be considered and necessitates careful surveillance in patients receiving both radiotherapy and ICIs.

Plain language summary

Sometimes cancer patients receive a type of treatment called radiotherapy, which uses high-energy beams to target the cancer. This treatment is very helpful, but when applied to the chest, it can cause problems in the blood vessels of the heart many years later, a condition called radiation-induced heart disease. This report is about a 63-year-old man who developed this heart problem much sooner than usual, just 3 years after receiving radiation treatment for lung cancer. Alongside radiotherapy, he also received two advanced kinds of cancer treatments. One helped his immune system to better identify and fight the cancer, and the other worked to stop the cancer from getting the blood supply it needs to grow. Our report suggests that these new treatments may interact with radiotherapy in a way that causes heart problems more quickly. This is especially important to consider in patients without previous heart problems. Our findings remind doctors to closely monitor the heart health of patients receiving these treatments and point to the need for more research into how these treatments may affect the heart when used together.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Ravenholt RT. California chiropractors. An epidemiological study of causes of death among them and other characteristics. Calif. Med. 101(5), 341–347 (1964).
Medline CASGoogle Scholar
2. Donnellan E, Phelan D, McCarthy CP, Collier P, Desai M, Griffin B. Radiation-induced heart disease: a practical guide to diagnosis and management. Cleve. Clin. J. Med. 83(12), 914–922 (2016).
MedlineGoogle Scholar
3. Fajardo LF, Stewart JR. Experimental radiation-induced heart disease. I. Light microscopic studies. Am. J. Pathol. 59(2), 299–316 (1970).
Medline CASGoogle Scholar
4. Pedersen LN, Schiffer W, Mitchell JD, Bergom C. Radiation-induced cardiac dysfunction: practical implications. Kardiol. Pol. 80(3), 256–265 (2022).
MedlineGoogle Scholar
5. Garg A, Kumar P. Dosimetric comparison of the heart and left anterior descending artery in patients with left breast cancer treated with three-dimensional conformal and intensity-modulated radiotherapy. Cureus 14(1), e21108 (2022).
MedlineGoogle Scholar
6. Pezner RD. Coronary artery disease and breast radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 86(5), 816–818 (2013).
MedlineGoogle Scholar
7. Darby SC, Ewertz M, Mcgale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368(11), 987–998 (2013). •• These publications furnish a detailed perspective for cardio-oncology and cardiology professionals, framing the management challenges and strategies against the backdrop of a modern understanding of radiation therapy’s impact on cardiac health. They underscore the need to navigate patient care with a nuanced appreciation of the potential or actual cardiac complications arising from such treatments.
Medline CASGoogle Scholar
8. Lancellotti P, Nkomo VT, Badano LP et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 26(9), 1013–1032 (2013).
MedlineGoogle Scholar
9. Atkins KM, Bitterman DS, Chaunzwa TL et al. Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 110(5), 1473–1479 (2021). •• These publications presented the correlation of left anterior descending coronary artery dose and the risk of major adverse cardiac events, serving as the landmarks in cardio-oncology for lung cancer radiation therapy.
MedlineGoogle Scholar
10. Atkins KM, Rawal B, Chaunzwa TL et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J. Am. Coll. Cardiol. 73(23), 2976–2987 (2019).
MedlineGoogle Scholar
11. van Nimwegen FA, Schaapveld M, Cutter DJ et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J. Clin. Oncol. 34(3), 235–43 (2016).
Medline CASGoogle Scholar
12. Van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med. 175(6), 1007–1017 (2015).
MedlineGoogle Scholar
13. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin. Proc. 91(1), 81–83 (2016).
MedlineGoogle Scholar
14. Atkins KM, Chaunzwa TL, Lamba N et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol. 7(2), 206–219 (2021). •• These publications presented the correlation of left anterior descending coronary artery dose and the risk of major adverse cardiac events, serving as the landmarks in cardio-oncology for lung cancer radiation therapy.
MedlineGoogle Scholar
15. Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther. 7(1), 258 (2022).
MedlineGoogle Scholar
16. Du S, Zhou L, Alexander GS et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J. Thorac. Oncol. 13(4), 510–520 (2018).
Medline CASGoogle Scholar
17. Yegya-Raman N, Lee SH, Friedes C et al. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother. Oncol. 190, 110005 (2024).
Medline CASGoogle Scholar
18. Lyon AR, López-Fernández T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. Cardiovasc. Imaging 23(10), e333–e465 (2022).
MedlineGoogle Scholar
19. Saro H, Armenian et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO 35, 893–911 (2017).
MedlineGoogle Scholar
20. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 19(9), e447–e458 (2018).
Medline CASGoogle Scholar
21. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J. Am. Coll. Cardiol. 70(20), 2536–2551 (2017).
MedlineGoogle Scholar
22. Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin. Interv. Cardiol. 3(3–4), 163–172 (1998).
Medline CASGoogle Scholar
23. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 61(23), 2319–2328 (2013).
MedlineGoogle Scholar
24. Balanescu DV, Donisan T, Dayah T et al. Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. Int. J. Cardiovasc. Imaging 35(5), 759–760 (2019).
MedlineGoogle Scholar
25. Hussey P, Wu I, Johnston T. 2018 ACC/HRS/NASCI/SCAI/SCCT expert consensus document on optimal use of ionizing radiation in cardiovascular imaging: best practices for safety and effectiveness – a review for the cardiac anesthesiologist. J. Cardiothorac. Vasc. Anesth. 33(11), 2902–2908 (2019).
MedlineGoogle Scholar
26. Venkatesulu BP, Mahadevan LS, Aliru ML et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl. Sci. 3(4), 563–572 (2018).
MedlineGoogle Scholar
27. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart 104(20), 1647–1653 (2018).
MedlineGoogle Scholar
28. Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br. Heart J. 69(6), 496–500 (1993).
Medline CASGoogle Scholar
29. Om A, Vetrovec GW. Coronary angioplasty of radiation-induced stenosis. Am. Heart J. 125(4), 1164–1166 (1993).
Medline CASGoogle Scholar
30. McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am. J. Cardiol. 60(13), 1020–1024 (1987).
Medline CASGoogle Scholar
31. Ruiz CR, Mesa-Pabón M, Soto K, Román JH, López-Candales A. Radiation-induced coronary artery disease in young patients. Heart Views 19(1), 23–26 (2018).
MedlineGoogle Scholar
32. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc. Interv. 79(3), 453–495 (2012).
MedlineGoogle Scholar
33. Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin. Oncol. (R. Coll. Radiol.) 17(3), 153–159 (2005).
Medline CASGoogle Scholar
34. Dezorzi C. Radiation-induced coronary artery disease and its treatment: a quick review of current evidence. Cardiol. Res. Pract. 2018, 8367268 (2018). •• These publications furnish a detailed perspective for cardio-oncology and cardiology professionals, framing the management challenges and strategies against the backdrop of a modern understanding of radiation therapy’s impact on cardiac health. They underscore the need to navigate patient care with a nuanced appreciation of the potential or actual cardiac complications arising from such treatments.
MedlineGoogle Scholar
35. Darby SC, Cutter DJ, Boerma M et al. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76(3), 656–665 (2010).
MedlineGoogle Scholar
36. Bradley JD, Hu C, Komaki RR et al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 38(7), 706 (2020).
Medline CASGoogle Scholar
37. Lee SH, Geng H, Arnold J et al. Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617. Int. J. Radiat. Oncol. Biol. Phys. 117(5), 1270–1286 (2023).
MedlineGoogle Scholar
38. Demirci S, Nam J, Hubbs JL, Nguyen T, Marks LB. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 980–987 (2009).
MedlineGoogle Scholar
39. Rehammar JC, Jensen MB, McGale P et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005. Radiother. Oncol. 123(2), 299–305 (2017).
MedlineGoogle Scholar
40. Yeboa DN, Evans SB. Contemporary breast radiotherapy and cardiac toxicity. Semin. Radiat. Oncol. 26(1), 71–78 (2016).
MedlineGoogle Scholar
41. Marks LB, Yorke ED, Jackson A et al. Use of normal tissue complication probability models in the clinic. Int. J. Radiat. Oncol. Biol. Phys. 76(Suppl. 3), S10–S19 (2010).
MedlineGoogle Scholar
42. Brown KN, Hussain K, Richards JR. Radiation induced coronary artery disease. In: StatPearls. StatPearls Publishing, FL, USA (2022).
Google Scholar
43. Task Force Members, Montalescot G, Sechtem U et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34(38), 2949–3003 (2013).
MedlineGoogle Scholar
44. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42(34), 3227–3337 (2021).
MedlineGoogle Scholar
45. Wei J, Xu H, Liu Y, Li B, Zhou F. Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget 8(13), 20842–20850 (2017).
MedlineGoogle Scholar
46. Wilkinson EL, Sidaway JE, Cross MJ. Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells. J. Cell. Physiol. 233(1), 186–200 (2018).
Medline CASGoogle Scholar
47. O’Herron T, Lafferty J. Prophylactic use of colchicine in preventing radiation induced coronary artery disease. Med. Hypotheses 111, 58–60 (2018).
MedlineGoogle Scholar
48. Annest LS, Anderson RP, Li W, Hafermann MD. Coronary artery disease following mediastinal radiation therapy. J. Thorac. Cardiovasc. Surg. 85(2), 257–263 (1983).
Medline CASGoogle Scholar
49. Veeragandham RS, Goldin MD. Surgical management of radiation-induced heart disease. Ann. Thorac. Surg. 65(4), 1014–1019 (1998).
Medline CASGoogle Scholar
50. Schömig K, Ndrepepa G, Mehilli J, Pache J, Kastrati A, Schömig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc. Interv. 70(3), 359–365 (2007).
MedlineGoogle Scholar
51. Caio G. Myocarditis with immune checkpoint blockade. N. Engl. J. Med. 376(3), 291–292 (2017).
MedlineGoogle Scholar
52. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375(18), 1749–1755 (2016).
MedlineGoogle Scholar
53. Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc. Res. 115(5), 869–877 (2019).
Medline CASGoogle Scholar
54. Wang WX, Song ZZ, Zhang YP. Cardiovascular toxicities associated with immune checkpoint inhibitors. Zhonghua Zhong Liu Za Zhi 42(7), 609–613 (2020).
Medline CASGoogle Scholar
55. Grabie N, Gotsman I, Dacosta R et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8⁺ T-cell mediated injury in the heart. Circulation 116(18), 2062–2071 (2007).
Medline CASGoogle Scholar
56. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317–325 (2011).
Medline CASGoogle Scholar
57. Zhao TX, Mallat Z. Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73(13), 1691–1706 (2019).
Medline CASGoogle Scholar
58. Bu DX, Tarrio M, Maganto-Garcia E et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31(5), 1100–1107 (2011).
Medline CASGoogle Scholar
59. Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol. 174(22), 3940–3955 (2017).
Medline CASGoogle Scholar
60. Gelsomino F, Fiorentino M, Zompatori M et al. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 29(1), 284–286 (2018). •• These studies highlight the risk of acute coronary syndrome associated with the use of nivolumab, prompting a valid concern that prior or concurrent use of nivolumab following thoracic radiotherapy may precipitate the early onset of radiation-induced coronary artery disease. Hence, as cancer therapies evolve, it is imperative that our comprehension of their potential cardiovascular impacts advances accordingly.
Medline CASGoogle Scholar
61. Cautela J, Rouby F, Salem JE et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can. J. Cardiol. 36(4), 476–481 (2020). •• These studies highlight the risk of acute coronary syndrome associated with the use of nivolumab, prompting a valid concern that prior or concurrent use of nivolumab following thoracic radiotherapy may precipitate the early onset of radiation-induced coronary artery disease. Hence, as cancer therapies evolve, it is imperative that our comprehension of their potential cardiovascular impacts advances accordingly.
MedlineGoogle Scholar
62. Son C, Moey MYY, Walker PR, Naqash AR, Peach MS, Ju AW. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front. Oncol. 12, 1025455 (2022).
Medline CASGoogle Scholar
63. Calabretta R, Hoeller C, Pichler V et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 142(24), 2396–2398 (2020).
Medline CASGoogle Scholar
64. Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc. Pathol. 43, 107148 (2019).
Medline CASGoogle Scholar
65. Drobni ZD, Alvi RM, Taron J et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142(24), 2299–2311 (2020).
Medline CASGoogle Scholar
66. Cheng Y, Nie L, Ma W, Zheng B. Early onset acute coronary artery occlusion after pembrolizumab in advanced non-small cell lung cancer: a case report. Cardiovasc. Toxicol. 21(8), 683–686 (2021).
Medline CASGoogle Scholar
67. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377(20), 1919–1929 (2017).
Medline CASGoogle Scholar
68. Jabbour SK, Lee KH, Frost N et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 7(9), 1–9 (2021).
MedlineGoogle Scholar

Vol. 16, No. 6

Supplemental Materials

Metrics

Downloaded 98 times

History

Received 2 April 2023

Accepted 5 January 2024

Published online 5 February 2024

Published in print April 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2023-0084

Author contributions

X Qian contributed to investigation, data collection and drafting of the manuscript. K Ding contributed to the investigation and the verification of data. Y Lu contributed to critical revisions for intellectual content and gave final approval. All authors had final responsibility for the decision to submit for publication.

Acknowledgments

The authors would like to thank their colleagues at the Department of Radiation Oncology and wish to acknowledge the support provided by the Department of Cardiology at the Affiliated Lihuili Hospital, Ningbo University.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained verbal and written informed consent from the patient/patients for the inclusion of their medical and treatment history within this case report.

PDF download

Radiation-induced coronary artery disease during immune checkpoint inhibitor therapy: a case report

Abstract

Plain language summary

References